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Summary
Background:  Prevention  of  tuberculosis  (TB)  in  the  United  States  usually  involves
testing  for  latent  tuberculosis  infection  (LTBI)  with  a tuberculin  skin  test  (TST),
followed  by  offering  therapy  to  those  who  have  a  positive  test  result.  QuantiFERON-
TB  Gold  assay  (QFT-G)  is  more  speciﬁc  for  infection  with  Mycobacterium  tuberculosis
than  the  TST,  especially  among  persons  vaccinated  with  bacillus  Calmette-Guérin,
thereby  reducing  the  number  of  false  positive  tests.
Methods:  Adults  referred  to  a  pulmonary  clinic  for  a  positive  TST  result  were  tested
with  QFT-G.  We  assessed  factors  for  having  a  positive  QFT-G.
Results:  Among  100  adults  who  were  BCG-vaccinated  and  had  a  positive  TST  result,
30  (30%)  had  a  positive  result  using  QFT-G.  Persons  from  high-incidence  countries
were  8.2  times  more  likely  to  have  a  positive  QFT-G  result  compared  with  persons
from  low-incidence  countries  (46%  versus  9%).  Using  logistic  regression  to  assess
QFT-G  positivity,  strong  predictors  included  having  an  abnormal  chest  radiograph
consistent  with  healed  TB,  a  TST  induration  of  ≥16  mm,  and  birth  in  a high-incidence
country.
Conclusion:  Use  of  QFT-G  assay  following  a  positive  TST  result  further  identiﬁes
persons  who  would  most  beneﬁt  from  treatment  for  LTBI.
©  2012  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.
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n  integral  component  of  tuberculosis  (TB)  con-
rol in  the  United  States  is  the  identiﬁcation  and
 Sciences. Published by Elsevier Ltd. All rights reserved.
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treatment  of  persons  with  latent  tuberculosis
infection (LTBI)  [1].  Approximately  10%  of  per-
sons infected  with  Mycobacterium  tuberculosis  (M.
tuberculosis) develop  TB  disease.  However,  the  risk
of developing  TB  varies,  and  recently  infected  per-
sons have  an  increased  risk  for  TB  disease  [2,3].  One
group for  whom  screening  is  recommended  is  per-
sons recently  arrived  from  areas  of  the  world  with  a
high incidence  of  TB,  many  of  whom  have  been  vac-
cinated with  Bacillus  Calmette-Guérin  (BCG)  [4].
LTBI  has  historically  been  diagnosed  using  the
tuberculin  skin  test  (TST).  The  interpretation  of  the
TST requires  knowledge  of  a  person’s  medical  and
epidemiologic  factors  to  determine  the  threshold  at
which the  reaction  is  considered  positive.  Because
the puriﬁed  protein  derivative  used  in  the  TST  is a
poorly deﬁned  mixture  of  antigens  shared  by  the  M.
tuberculosis  complex,  including  wild  type  Mycobac-
terium  bovis,  M.  bovis  var.  BCG,  and  several  other
species of  mycobacteria,  it  results  in  a  speciﬁcity  of
approximately  60%  in  BCG-vaccinated  populations
[5]. The  lack  of  speciﬁcity  of  the  TST  for  M.  tuber-
culosis has  led  to  the  inappropriate  diagnosis  of
some patients  with  LTBI  and  to  the  development
of alternative  tests.
Interferon-  release  assays  (IGRAs),  including
QuantiFERON-TB-Gold  (QFT-G),  represent  a  new
class of  tests  that  has  been  approved  by  the  Federal
Drug  Administration  for  the  diagnosis  of  LTBI.  The
QFT-G test  uses  an  enzyme-linked  immunosorbent
assay to  measure  the  concentration  of  interferon-
released by  activated  T-lymphocytes  after  stim-
ulation by  antigens  that  are  speciﬁc  to  the  M.
tuberculosis  complex,  are  widely  absent  in  nontu-
berculous  mycobacteria,  and  more  importantly,  are
not expressed  in  BCG  [6].  Thus,  IGRAs,  such  as  QFT-
G, might  be  particularly  useful  to  test  for  LTBI  in
persons who  have  been  vaccinated  with  BCG  [7].
The higher  speciﬁcity  of  QFT-G  and  other  IGRAs
compared with  the  TST  can  be  used  to  eliminate
the unnecessary  treatment  of  persons  with  false-
positive  TSTs.
The aims  of  this  study  were  (1)  to  determine
the percentage  of  QFT-G  positivity  in  persons  with
a history  of  BCG  vaccination  who  had  a  positive
TST result  and  (2)  to  identify  patient  characteristics
that might  predict  a  positive  QFT  test  result.
MethodsPatients  with  a  positive  TST  result  were  referred
by local  providers  to  the  pulmonary  clinic  that
serves as  a  referral  center  for  the  greater  Hart-
ford metropolitan  area  for  medical  evaluations  to
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xclude  TB  disease.  Patients  aged  ≥18  years  with
 documented  positive  TST  result  (≥10  mm  indura-
ion or  ≥5  mm  with  a  chest  radiograph  consistent
ith pulmonary  TB)  who  presented  to  the  clinic
rom June  2008  to  December  2009  were  included
n this  study.  Patients  were  asked  whether  they
ad received  a BCG  vaccination,  and  those  who
id not  know  their  vaccination  status  were  visually
nspected  for  a vaccination-related  scar.  A  QFT-G
est was  performed  at  the  time  of  this  visit;  testing
as performed  at  a  single  large  commercial  lab-
ratory. The  QFT-G  test  results  were  interpreted
ccording to  the  manufacturer’s  instructions  [8].
ctive TB  disease  was  excluded  using  symptom
eview, physical  examination,  chest  radiography,
nd, if  necessary,  sputum  collection  for  acid-fast
acilli  smear  microscopy  and  mycobacterial  cul-
ure.
Clinic providers  reviewed  the  medical  records
nd extracted  data  including  age,  gender,  coun-
ry of  origin,  length  of  residence  in  the  United
tates, TST  reaction  size  measured  in  millimeters
f induration,  chest  radiograph  ﬁndings,  and  risk
actors for  the  development  of  TB  disease.  A  high-
ncidence  country  was  deﬁned  as  a  country  with  an
ncidence of  ≥20  cases  of  acid-fast  smear-positive
ulmonary TB  per  100,000  persons  [9].  A  step-wise
ogistic  regression  was  used  to  determine  the  odds
atios (ORs)  for  demographic  and  clinical  factors
hat  were  predictive  of  a positive  QFT-G  result.
ge and  TST  induration  were  modeled  as  contin-
ous variables.  A  P  value  of  <0.05  was  considered
igniﬁcant.
A review  of  the  study  determined  that  it  entailed
n assessment  of  routine  public  health  practice  and
as not  considered  human  subjects  research.  The
nstitutional  Review  Board  of  St.  Francis  Hospital
nd Medical  Center  (Hartford,  CT)  approved  this
etrospective  cohort  study.
esults
 total  of  100  BCG-vaccinated  adults  who  were
eferred to  the  pulmonary  clinic  because  of  a  pos-
tive TST  result  were  included  in  the  study.  The
edian  patient  age  was  34  years,  nearly  half  (46%)
ere male,  and  the  study  participants  had  been
n the  United  States  for  a median  duration  of  4.5
ears (range  0—44  years).  The  participants  were
rom 42  different  countries  representing  the  Amer-
cas (47%),  Europe  (20%),  Africa  (18%),  Southeast
sia (6%),  the  western  Paciﬁc  (6%),  and  the  east-
rn Mediterranean  (3%).  Their  birth  countries  had
 median  TB  incidence  of  37  cases  per  100,000
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aigure  1  Distribution  of  positive  TST  (mm  induration)
nd  QuantiFERON-TB  Gold.
opulation  (range  2—312  cases);  57%  were  from
ountries  with  a  high  incidence  of  TB.  The  median
ST induration  was  15  mm.
Among  the  100  persons  with  positive  TST  results,
0 (30%)  also  had  a  positive  QFT-G  result  (Fig.  1).
ne QFT-G  result  was  indeterminate,  but  a repeat
est  was  negative.  Twenty-six  (46%)  of  the  57  adults
rom high-incidence  countries  were  QFT-G  positive
Table  1);  in  contrast,  4  of  43  adults  (9%)  from
ow-incidence countries  were  positive  (OR  =  8.2;
5% conﬁdence  interval  (CI),  2.4—31.1).  None  had
ctive TB  disease.
A logistic  regression  was  used  to  compare
uberculin  reactivity.  Persons  with  a  TST  indura-
ion ≥  16  mm  had  a  more  than  six  fold  greater
ikelihood of  having  a  positive  QFT-G  result  than
ersons  with  a  smaller  TST  induration  (Table  2).  The
ombination  of  being  from  a  high-incidence  country
nd having  a  TST  induration  ≥  16  mm  also  strongly
redicted  QFT-G  positivity  (Table  2).  Eight  persons,
ncluding  seven  from  high-incidence  countries,  had
hest radiographs  consistent  with  a  prior,  healed
B infection  and  negative  mycobacterial  cultures;
Table  1  Tuberculin  skin  test  and  QuantiFERON-TB-
Gold  results  stratiﬁed  by  the  tuberculosis  incidence  in
the  patient’s  country  of  origin.
Low  TB
incidence
(n  =  43)
High  TB
incidencea
(n  =  57)
TST  <  16  mm
QFT-G  negative  27  24
QFT-G  positive  0  9
TST  ≥  16  mm
QFT-G  negative  12  7
QFT-G  positive  4  17
TST, tuberculin skin test; QFT-G, QuantiFERON-TB Gold.
a High TB incidence deﬁned as acid-fast smear positive
pulmonary tuberculosis ≥ 20 cases/100,000 population.
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he  seven  patients  from  high-incidence  countries
lso had  a  positive  QFT-G  result  (OR  = 21.0;  95%  CI,
.4—179.9).  No  patients  were  diagnosed  with  TB
isease.
iscussion
n  this  study  of  100  BCG-vaccinated  adults  with  pos-
tive TST  results,  30%  also  had  a  positive  QFT-G
esult. The  strongest  predictors  of  a  positive  QFT-
 result  were  TST  induration  ≥  16  mm,  being  from
 high-incidence  country,  and  having  evidence  of
 previous,  healed  TB  infection  on  a chest  radio-
raph. These  ﬁndings  verify  the  results  reported
y a  Canadian  TB  clinic,  which  used  a similar
pproach that  resulted  in  a  signiﬁcant  reduction
f the  number  of  patients  who  were  treated  for
TBI [10].  In  the  Canadian  study,  researchers  also
bserved  that  a  positive  QFT-G  result  was  associ-
ted with  the  factors  found  in  our  study,  in  addition
o increasing  age.  Additionally,  our  study  showed
hat persons  with  a positive  TST  and  a  positive  QFT
esult were  more  likely  to  have  pulmonary  abnor-
alities  suggestive  of  previous  TB  disease.  This  is
n important  ﬁnding  because  these  persons  are  at
igh risk  for  developing  TB  disease  and  are  priority
andidates  for  treatment  for  LTBI  once  TB  disease
s excluded.  In  BCG-vaccinated  persons  with  a  posi-
ive TST  result  observed  at  a  TB  clinic  in  Cleveland,
H, USA,  male  sex  and  a shorter  time  since  arrival  in
he United  States  were  also  signiﬁcantly  associated
ith  a  positive  IGRA  result  [11].
The  advent  of  IGRAs  and  their  increasing  avail-
bility  is  having  an  important  impact  on  setting
riorities  for  the  treatment  of  LTBI  in  an  era  of
imited  and  decreasing  resources  [12].  Approaches
o reducing  the  number  of  lower-risk  persons  who
re started  on  treatment  include  using  QFT-G  as
he test  of  choice  for  persons  who  have  had  BCG
accination or  using  an  IGRA  to  verify  LTBI  in
hose who  have  a  positive  TST  result.  Although  the
ensitivity  of  IGRA  is  similar  to  that  of  the  TST
n patients  with  culture-conﬁrmed  TB,  proponents
f doing  two  tests  (a  TST  followed  by  an  IGRA
or those  who  have  a  positive  TST  result)  high-
ight the  speciﬁcity  of  IGRAs,  which  approaches
94% in  BCG-vaccinated  persons  [5].  In  contrast,
he speciﬁcity  of  the  TST  is  relatively  low  and
s heterogeneous  in  BCG-vaccinated  persons,  ran-
ing between  35%  and  79%.  These  test  parameters
uggest that,  in  BCG-vaccinated  persons,  an  IGRA
hould be  the  preferred  test  [13].
There  is  evidence  suggesting  that  persons  with  a
ositive TST  result  and  a negative  QFT-G  result  are
372  H.  Chawla  et  al.
Table  2  Factors  predictive  of  a  positive  QuantiFERON-TB-Gold  test  result  among  100  BCG-vaccinated  adults  with
a  positive  tuberculin  skin  test  result.
Characteristic  Persons  with
characteristic
(N  =  100)
Adjusted  odds  ratio  for  a
positive  QFT-G  result
(95%CI)
P value
TST  ≥  16  mm  40%  6.3  (2.2—18.0)  <0.001
High  incidence  area 57%  8.2  (2.4—34.1)  <0.001
High  incidence  and  TST  ≥  16  mm 24% 11.8  (3.6—39.7) <0.001
Abnormal  chest  X-ray 8%  21.0  (2.4—179.9) <0.001
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RQFT-G, QuantiFERON-TB Gold; TST, tuberculin skin test.
at  low  risk  for  developing  TB  disease.  In  a  German
study of  954  close  contacts  of  culture-conﬁrmed
pulmonary  TB  patients,  treatment  for  LTBI  was
offered  only  to  those  who  had  a  positive  QFT-G
result [14].  None  of  the  treated  patients  devel-
oped TB  disease.  In  contrast,  among  untreated
contacts, only  3.1%  of  TST-positive  [>5  mm]  and
QFT-G-negative  contacts  developed  disease,  while
12.9% of  contacts  with  a  positive  QFT-G  result
developed TB  disease.
Despite  data  that  support  the  use  of  IGRAs
among BCG-vaccinated  persons,  there  continue  to
be several  barriers  to  the  widespread  adoption  of
these tests.  First,  the  national  guidelines  recom-
mending  the  use  of  IGRAs  to  diagnose  LTBI  are
not uniformly  implemented  in  practice  [15].  The
most favored  approach  internationally,  particularly
among  BCG-vaccinated  populations,  is  to  test  with
a TST  followed  by  an  IGRA  if  the  TST  result  is  pos-
itive. The  two-test  strategy  stands  in  contrast  to
the one-test  (preferably  IGRA)  approach  for  BCG-
vaccinated  persons  advocated  in  the  United  States
[13]. However,  clinicians  might  see  patients  who
had a  TST  performed  in  another  setting.  Faced
with the  unknown  quality  of  a  TST  performed
in another  location,  tests  are  often  repeated.
Second, the  costs  and  logistics  of  testing  are
important limitations.  In  Connecticut,  both  major
commercial  laboratories  offer  QFT  testing,  as  do
some hospitals,  but  the  cost  of  obtaining  a  QFT
test can  vary  widely  for  patients  who  are  unin-
sured. The  Department  of  Public  Health  Laboratory
offers  QFT  testing  but  restricts  it  to  patients
who are  uninsured  or  underinsured  or  treated
at a  local  health  department  clinic.  Additionally,
the requirements  for  specimen  collection,  deliv-
ery to  the  laboratory,  and  maintaining  laboratory
quality assurance  can  make  obtaining  an  IGRA
challenging.  Although  several  studies  have  shown
the cost  effectiveness  of  IGRAs  in  testing  for  TB,
these initial  barriers  to  obtaining  testing  can  make
the realization  of  potential  cost  savings  difﬁcult
[16—18].The  main  limitation  of  this  study  is  the  low  num-
er of patients.  However,  our  results  are  consistent
ith those  from  other  settings,  which  suggests  that
hese ﬁndings  apply  to  our  study  population  as  well.
he retrospective  nature  of  this  study  means  that
e could  not  control  for  the  quality  of  the  TST
mong persons  referred  to  the  clinic.  Nevertheless,
he referring  providers  are  accustomed  to  screening
ersons  at  risk  for  LTBI,  so  any  biases  are  largely
hose inherent  to  the  TST.
This study  demonstrates  the  real-world  expe-
ience of  a referral  pulmonary  clinic  in  using
he QFT-G  test  among  a  group  of  BCG-vaccinated
dults. While  IGRAs  can  be  helpful  in  targeting  cer-
ain patients  for  LTBI  treatment,  clinicians  should
lso have  a low  threshold  to  start  treatment  for  LTBI
n persons  from  a country  with  a high  incidence  of
B and  a  positive  TST  result,  particularly  for  those
ith indurations  >  15  mm)  [19].
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